Evaluasi Jumlah Sel T-CD4 dan Berat Badan Anak dengan HIV/AIDS yang Mendapatkan Anti Retro Virus Lini Pertama di Rumah Sakit Dr. Saiful Anwar Malang
Sari
Latar belakang. Infeksi HIV merupakan masalah di dunia dan juga Indonesia. Peningkatan kejadian pada ibu hamil juga meningkatkan kasus HIV anak. Virus HIV menginfeksi dan menurunkan jumlah sel T CD4 sehingga menambah risiko terjadi infeksi oportunistik dan memperburuk gizi.
Tujuan. Mengevaluasi jumlah sel T CD4 dan berat badan pada pemberian anti retro virus (ARV) terhadap anak HIV/AIDS di RSU dr Saiful Anwar Malang.
Metode. Penelitian longitudinal mengukur CD4 dan perubahan berat badan pada anak HIV/AIDS dengan ARV lini pertama (zidovudine, lamivudine, nevirapine) lebih dari 6 bulan. Data disajikan dalam tabel dan gambar.
Hasil. Terdapat 13 kasus HIV (dari total 40) dengan ARV ≥6 bulan, tanpa kasus meninggal. Rerata peningkatan berat badan setelah 6 bulan 29,6% (12 kasus), 1 kasus berat badan turun 2,1%, 6 bulan – 1 tahun 8,7% (11 kasus), 1 kasus berat badan turun 8%. Rerata peningkatan berat badan dalam kurun, Waktu 1–1,5 tahun 7,9% (pada 6 kasus), 1,5–2 tahun 6,5% (3 kasus), 1 kasus berat badan turun 2%, rerata peningkatan berat badan 2–2,5 tahun 11,5% (2 kasus), dan 1 kasus telah mencapai 3 tahun pengobatan (berat badan meningkat 19,1%). Jumlah sel T CD4 cenderung meningkat pada 11 kasus dan menurun pada 2 kasus.
Kesimpulan. Terdapat peningkatan jumlah sel T CD4 dan berat badan anak HIV/AIDS dengan ARV ≥6 bulan. Obat ARV lini pertama masih dapat digunakan, perlu dipertimbangkan ARV lini kedua pada dua kasus yang mengalami kegagalan terapi.
Kata Kunci
Teks Lengkap:
PDFReferensi
Neisheim SR, Kapogiannis BG, Soe MM, Sullivan KM, Abrams E, Farley J, dkk. Trends in Opportunistic Infections in the Pre– and Post–Highly Active Antiretroviral Therapy Eras Among HIV-Infected Children in the Perinatal AIDS Collaborative Transmission Study, 1986–2004. Pediatrics 2007; 120:100-9.
Bolton-Moore C, Mwangelwa Mubiana-Mbewe, Cantrell EA. Clinical outcomes and CD4 cell response in children receiving antiretroviral therapy at primary health care facilities in Zambia. JAMA 2007;298:1888-99.
Depkes RI. Pedoman tata laksana infeksi HIV dan pengobatan antiretroviral pada anak di Indonesia. 2008.
Jansenns B, Raleigh B, Soeung S, Akaob K, Te V, Gupta J, dkk. Effectiveness of highly active antiretroviral therapy in HIV-positive children: evaluation at 12 months in a routine program in Cambodia Pediatrics 2007;120:e1134-e1140.
Song R, Jelagat J, Dzombo D, Mwalimu M, Mandaliya K, Shikely K, Essajee S, dkk. Efficacy of highly active antiretroviral therapy in HIV-1–infected children in Kenya. Pediatrics 2007;120;e856-e61.
Larru B, Resino S, Bello JM, de Jose MI, Fortuny C, Navarro ML, dkk. Long-term response to highly active antiretroviral therapy with lopinavir/ritonavir in pre-treated vertically HIV-infected children. J Antimicrob Chemother 2008;61:183–90.
Cowburn C, Hatherill M, Eley B, Nuttall J, Hussey G, Reynolds L, dkk. Short-term mortality and implementation of antiretroviral treatment for critically ill HIV-infected children in a developing country. Arch Dis Child 2007;92:234-41.
Kumarasamy N, Venkatesh KK, Devaleenol B, Poongulali, Mothi SN, Solomona S. Safety, tolerability and effectiveness of generic HAART in HIV-infected children in South India. J Trop Pediatr 2008;55:155-9.
Foster C, Lyall H. HIV and mitochondrial toxicity in children. J Antimicrob Chemother 2008; 61: 8–12.
Peter L. Havens, MD, Lynne M. Mofenson, MD, Committee on Pediatric AIDS. Evaluation and management of the infant exposed to HIV-1 in the United States. Pediatrics 2009;123:175-87.
Read JS, Committee on Pediatric AIDS. Diagnosis of HIV-1 infection in children younger than 18 months in the United States. Pediatrics 2007;120;e1547-e62.
Violari A, Cotton MF, Gibb DM, Babiker AG, Steyn J, Madhi SA, dkk. Early antiretroviral therapy and mortality among HIV-infected infants. N Engl J Med 2008;359:2233-44.
Drain PK, Kupka R, Mugusi F, and Fawzi WW. Micronutrients in HIV-positive persons receiving highly active antiretroviral therapy. Am J Clin Nutr 2007; 85: 333–45.
Winters MA, Merigan TC. Insertions in the human immunodeficiency virus type 1 protease and reverse transcriptase genes: clinical impact and molecular mechanisms. Antimicrob Agents Chemother 2005; 49:2575-82.
Barbour JD, Deeks SG. Clinical implications of HIV fitness and virulence. Dalam: Volberding PA, Sande MA, Lange J, Greene WC, penyunting. Global HIV/AIDS medicine. China: Saunders Elsevier; 2008.h.161-9.
Brindeiro PA, Brindeiro RM, Mortensen C, Hertogs K, De Vroey V, Rubini NPM, dkk. Testing genotypic and phenotypic resistance in human immunodeficiency virus type 1 isolates of clade B and other clades from children failing antiretroviral therapy. J Clin Microbiol 2002;40:4512-9.
Uzochukwu BSC, Onwujekwe OE, Onoka AC, Okoli C, Uguru NP, Chukwuogo OI. Determinants of non-adherence to subsidized anti-retroviral treatment in southeast Nigeria. Health Policy and Planning 2009;24:189-96.
Kapogiannis BG, Soe MM, Nesheim SR, Sullivan KM, Abrams E, Farley J, dkk. Trends in bacteremia in the pre- and post-highly active antiretroviral therapy era among HIV-infected children in the US perinatal AIDS collaborative transmission study (1986–2004). Pediatrics 2008;121:e1229-39.
Committee on Pediatric AIDS. Section on international child health. increasing antiretroviral drug access for children with HIV infection. Pediatrics 2007; 119: 838-45.
Ponnet M, Frederix K, Petdachai W, Wilson D, Eksaengsri A, Zacharia R. A drug dosage table is a useful tool to facilitate prescriptions of antiretroviral drugs for children in Thailand. Int J STD AIDS 2005;16:420-6.
DOI: http://dx.doi.org/10.14238/sp11.4.2009.276-81
Refbacks
- Saat ini tidak ada refbacks.
##submission.copyrightStatement##
##submission.license.cc.by-nc-sa4.footer##
Email: editorial [at] saripediatri.org
Sari Pediatri diterbitkan oleh Badan Penerbit Ikatan Dokter Anak Indonesia
Ciptaan disebarluaskan di bawah Lisensi Creative Commons Atribusi-NonKomersial-BerbagiSerupa 4.0 Internasional.